Cue Biopharma is trading 11.22% up at $25.78, with biotech-sector strength providing the primary support amid broader risk-on sentiment.
- XBI is up 2.06% during regular trading, providing a significant tailwind.
- The stock has sharply rebounded from the recent selloff.
- No new company-specific announcement dated August 25, 2026 was identified; the latest major disclosures were the August 14 second-quarter results and recent business updates.